Biome shares revenue target as part of Vision 27 Strategic Plan
Biome Australia Limited (ASX:BIO) has released a cumulative revenue target for the next three years from FY2025 and FY2027 of $75m to $85m. The target is a key component of Biome’s Vision 27 three-year strategic plan which will be released to the market later this quarter.
If achieved, the cumulative revenue target of $75m to $85m, would represent growth of more than 400% over the preceding periods target of $21m. It is worth noting that Biome surpassed this previous target by 14%, delivering a total of $24m in cumulative sales from FY2021 to FY2024. For FY2024, the actual result achieved was 30% over the target of $10m. Biome will continue to invest in growth whilst still growing profits.
Blair Norfolk commented on the release of the target saying:
“The team and I are energised about the next exciting growth phase as Biome becomes one of the most significant Australian and global companies in complementary medicine. We have built an incredible foundation and brand in Activated Probiotics, which is becoming a household name beyond the Australian market. Whilst we are incredibly proud of what we have achieved over the past three years, the next three years will be Biome’s greatest achievement yet.”
Biome achieved Canary Capital’s sales target of $13m in FY2024. Our target for FY2025 is $20.0m, a 54% increase over FY2024.
ASX AnnouncementAdd a New Post